Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
naltrexone + bupropion SR
- Development stage
- Unknown
- Lead developer
- Orexigen Therapeutics, Inc
- Modality
- Small Molecules
- Administration
- Intramuscular, Oral
01
Overview
This combination pharmacotherapy consists of extended-release injectable naltrexone and oral extended-release bupropion, specifically investigated by the National Institute on Drug Abuse (NIDA) for the treatment of methamphetamine use disorder. Naltrexone is a mu-opioid receptor antagonist that reduces the euphoric effects of substance use, while bupropion is a norepinephrine-dopamine reuptake inhibitor (NDRI) that addresses withdrawal symptoms and dysphoria. The combination was evaluated in the ADAPT-2 trial, demonstrating significant efficacy in increasing response rates among adults with moderate to severe methamphetamine use disorder compared to placebo. There is currently no FDA-approved medication for methamphetamine use disorder, making this combination a significant investigational treatment option.
- Other names
- naltrexone and bupropion SRNX/BUP
02
Targets
NET (Norepinephrine Transporter)KOR (Kappa opioid receptor)MOR (Mu opioid receptor)DOR (Opioid Receptor Delta 1)DAT (Dopamine plasma membrane transport protein)OCT2 (Organic cation transporter 2)
Beyond the preview
Go deeper on naltrexone + bupropion SR.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on naltrexone + bupropion SR.